Find your next paid study

Vanderbilt University Medical CenterNCT00898638

~$10 – $750

Metastatic MelanomaSquamous Cell Carcinoma of the Head and NeckNon-small Cell Lung Cancer

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)…

Iovance Biotherapeutics, Inc.NCT03645928

Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma

Official Title Targeted Dual Modality Imaging (TDMI) for Detection and Removal of Head and Neck Cancer

This phase I trial evaluates the safety and effectiveness of using two imaging techniques, indium In 111 panitumumab (111In-panitumumab) with single photon emi…

Vanderbilt-Ingram Cancer CenterNCT05945875

Solid Tumor, AdultMicrosatellite Stable Colorectal CancerHead and Neck Squamous Cell Carcinoma+10 more

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed…

KaliVir ImmunotherapeuticsNCT06444815

Solid TumorBiliary Tract CancerHead and Neck Squamous Cell Carcinoma+1 more

A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced…

TiumBio Co., Ltd.NCT05784688

Observational

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)

This trial tests how well personalized ultra fractionated stereotactic adaptive radiotherapy (PULSAR) works together with HyperArc© radiation treatment plannin…

Head and Neck CarcinomaLocalized Head and Neck CarcinomaMetastatic Head and Neck Carcinoma+1 more

Jonsson Comprehensive Cancer CenterNCT06572423

The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evide…

OncologyBreast CancerProstate Cancer+35 more

~$10 – $1,125

UMC UtrechtNCT04075305

Squamous Cell CarcinomaHead and Neck Cancer

Phase 2 Trial of Adaptive Radiotherapy Boost for Head and Neck Squamous Cell Carcinomas

The purpose of the study is to determine if it is feasible to use magnetic resonance imaging (MRI) to adjust a portion of radiation therapy for patients with h…

H. Lee Moffitt Cancer Center and Research InstituteNCT06137274

Prospective Data Registry and Quality of Life Assessment of PatientsUndergoing Radiotherapy With the RefleXion Medical Radiotherapy System (PREMIER Registry)

The purpose of this prospective cohort study is to assess clinical and quality of life measures as well as to define the severity of adverse effects for the us…

CancerCancer Central Nervous SystemCancer Thoracic+5 more

RefleXion MedicalNCT05406167

~$10 – $1,125

Head and Neck CancerSquamous Cell CarcinomaOral Cavity Cancer+6 more

Neoadjuvant Chemotherapy and PD-1 Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

The NeoScorch HN study is a single institution multisite phase II trial including 3 cohorts of 25 patients each for patients with newly diagnosed locoregionall…

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07209189

CarcinomaRecurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or aft…

NATCO Pharma Ltd.NCT05283226

Squamous Cell Carcinoma of Head and Neck

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas (LA-HNSCC)

The goal of this clinical trial is to learn if drug CADI-05, when used together with pembrolizumab (an FDA approved immunotherapy), can help treat locally adva…